The transitionbetween the two states causes structural conformational changes thatallow the protein to interact with the downstream effectors.312 HRAS mutations that lead to the aberrant activationof the protein are frequently found in different types of cancer,313 thus making HRAS a relevant drug target. The gene discussed is HRAS; the disease is cancer.